Objective: The objective of this descriptive study was to quantify the personal hygiene habits/practices of, as well as the over-the-counter (OTC) products used by, postmenopausal women. Specifically, we were interested in any product that would contact the vulva or vagina.
V ulvovaginal symptoms are common and have been reported by 9.6% to 44.4% of postmenopausal women. 1<3 Many women self-manage vulvovaginal symptoms with over-the-counter (OTC) medications and other alternative products. 4<8 Unfortunately, many commonly used OTC treatments and perineal hygiene practices (including talcum powder, topical benzocaine, and douching) have been shown to be harmful. 7<10 Despite evidence of harm from these products and hygiene practices in the medical literature, women continue to use these products and practices. 9, 10 Qualitative and quantitative studies have documented self-management practices and perineal hygiene habits among college-age women; however, studies among older women are lacking. 11<13 In addition to the products and practices that have been demonstrated to cause harm, any product that contacts the vulva or vaginal can cause an allergic reactionVcontact dermatitis. Avoiding vulvovaginal contact irritants has been advised as a first-line treatment of chronic vulvovaginal symptoms. 14, 15 Contact irritants can be present in both OTC products and products used for perineal hygiene.
Eliciting information on OTC treatments and perineal hygiene in postmenopausal women is necessary to better understand vulvovaginal symptoms in this population. Provider awareness about the full-spectrum OTC products used by postmenopausal women and their perineal hygiene habits is critical to be able to obtain an accurate history. The objective of this descriptive study was to quantify the personal hygiene habits/ practices of and OTC products used by postmenopausal women. Specifically, we were interested in any product that would contact the vulva or vagina.
METHODS
We performed a cross-sectional study of postmenopausal women seeking routine gynecologic care. Approval was sought and secured through the Institutional Review Board at Yale University.
Instrument development
We developed a questionnaire on the personal hygiene habits/practices of women and the OTC products that they use that would contact the vulva or vagina. To develop this questionnaire, we conducted two focus groupsVeach with five postmenopausal women aged 54 to 92 years who had vulvovaginal skin symptomsVto discuss OTC product use and perineal hygiene habits. Information obtained from these focus groups was used to develop a written questionnaire. Some women recognized brand names of products, whereas others recognized generic names (ie, Monistat A vs miconazole); therefore, both brand and generic names were included.
OTC treatments and perineal hygiene
Women were asked questions about their use of OTC treatments and their perineal hygiene in the last 3 months. OTC products were grouped into five major categories: barrier treatments, powders, topical anesthetics, OTC antifungals, and OTC topical steroids. Women were asked about perineal hygiene habits, including douching, sitz baths, soaps, and pubic hair grooming. Absorbent pad use is generally considered both as a product used for perineal hygiene and as a product used in the self-management of urinary incontinence and vaginal discharge. 16, 17 Women were asked about their current use of absorbent pads. Finally, women who answered Byes[ to the question BAre you currently sexually active?[ were asked questions specific for barrier protection and lubrication during coitus.
Participants and data collection
After developing the questionnaire, we recruited postmenopausal women seeking gynecologic care from two separate gynecology practices between June 2011 and August 2011. Women were approached for inclusion in this study after they consented to participate in a study validating the psychometric properties of a questionnaire examining vulvovaginal symptoms in postmenopausal women. 18 The target recruitment for the original study was 120 women.
Menopause was defined as the cessation of menses for 12 consecutive months or having both ovaries surgically removed. This definition was confirmed by women's self-report. Women were excluded if they had known vulvar dermatoses, including lichen sclerosus, lichen planus, psoriasis, Beh0et's disease, hidradenitis suppurativa, anorectal Crohn's disease, or genital herpes simplex virus. Exclusion criteria were first elicited by self-report and confirmed with the participants' medical records.
Urinary incontinence was defined as an affirmative answer to either question 2 or question 3 of the Urinary Distress Inventory-6: BDo you experienceI urine leakage related to a feeling of urgency?[ or BDo you experienceIurine leakage related to physical activity, coughing, or sneezing? [ 19 The questionnaire was a self-administered written instrument completed after an informed consent form had been obtained. Descriptive statistics were performed as appropriate to characterize the frequency of reported treatments and practices. Statistical analysis was conducted using STATA 11.0 (StatCorp Inc, College Station, TX).
RESULTS
The questionnaire on OTC treatments and perineal hygiene was completed by 114 postmenopausal women. Six women were approached and declined participation, for an overall response rate of 95%. The mean (SD) age was 66.1 (11.0) years ( Table 1) . Most women identified their race/ethnicity as non-Hispanic white (94.0%). Non-Hispanic black women represented 3.5% of the cohort, and Hispanic women represented 2.6% of the cohort. Any urinary incontinence was reported by 70 women (61.4%).
OTC treatments
Fifty-eight women (50.9%) reported using at least one OTC vulvovaginal treatment in the last 3 months, including barrier treatments, topical anesthetics, powders, and antifungals. Women often used more than one OTC product. Thirtyseven women (32.5%) reported the use of two or more OTC products. Twenty-eight (24.6%) women reported the use of barrier treatments (Table 2 ). Of women using barrier products, petroleum-based products (13 of 28; 46.4%) were the most commonly used, followed by zinc oxide (12 of 28; 42.3%). Powders were used by 34 women (29.8%). Talcum powder was the most commonly used powder (26 of 34; 76.5%). We did not find a statistical difference in talcum powder use based on body mass index (29.0 [1.2] vs 28.3 [0.70] kg/m 2 ; P = .64) or urinary incontinence (27.1% vs 15.9%; P = 0.16). The use of topical anesthetic products was reported by 14 women (12.3%). Use of OTC antifungals and OTC topical steroid treatments was also reported. Sixteen postmenopausal women (14.0%) reported any use of antifungal products, either prescription or OTC products, in the last 3 months. Of the women reporting antifungal product use, 43.8% (7 of 16) reported only using OTC antifungal products, 50% (8 of 16) used both OTC antifungal products and prescription treatment, and 6.3% (1 of 16) only used prescription treatments. Prescription treatments for vulvovaginal symptoms Systemic estrogens were used by 10 women (8.9%; Table 3 ). Three women (2.6%) used systemic estrogen/progesterone therapy. Topical prescription estrogens use was reported by 25 women (21.9%). Only one postmenopausal woman (0.9%) reported treatment of bacterial vaginosis within the last 3 months. Prescription topical corticosteroid use was reported by 11 women (9.6%).
Perineal hygiene habits
Nine postmenopausal women (7.9%) reported douching in the last 3 months (Table 4 ). Thirty percent of postmenopausal women reported using premoistened cleansing wipes for toilet hygiene, in addition to toilet paper. Most postmenopausal women (89 of 114; 78.1%) did not report performing any pubic hair grooming.
Absorbent products
More than 50% of women (60 of 114) used pantiliners, pads, or diapers for garment protection (Table 5 ). Only less than half of postmenopausal women (28 of 60; 47%) who used absorbent products reported the use of products specifically marketed for menstrual hygiene, not incontinence. 
Products used during sexual activity
Fifty women reported current sexual activity. Forty-six percent (23 of 50) of sexually active postmenopausal women reported using a product for lubrication with coitus ( Table 6 ). No women reported the use of natural oils (vegetable oil, olive oil, hazelnut oil, etc) for lubrication. Their partner's male condom use with coitus was reported by 9.6% (5 of 50) of women. No postmenopausal women reported spermicide use or female condom use.
DISCUSSION
In summary, we found that more than half of postmenopausal women seeking gynecologic care have used an OTC product for vulvovaginal symptoms in the last 3 months and that one third of women use two or more products. Because the use of OTC products is very common, our study highlights the need for a detailed history inquiry about OTC product use and perineal hygiene practices in the treatment of postmenopausal women.
Some OTC products can cause adverse reactions in women. For example, topical benzocaine, a common ingredient in OTC products marketed for itch relief, has been shown to cause severe contact dermatitis of the vulva. 7, 8 Absorbent products for garment protection are commonly used by postmenopausal women for the self-treatment of incontinence and for perineal hygiene. We found that, after the cessation of menses, postmenopausal women commonly use absorbent products, including menstrual hygiene products and products marketed for anti-incontinence protection. Severe contact vulvitis has been caused by ingredients in absorbent products and pads, including rosins, colophony, and methyldibromo glutaronitrile. 20<24 We found that more than 50% of postmenopausal women used pantiliners, pads, or diapers for garment protection in the last 3 months.
Besides products that cause allergic reactions, other products have been shown to cause harm.
The use of talc powderVthe main ingredient in baby powderVon the perineum has been questioned as early as the 1960s when it was found to be biologically similar to asbestos. 9 Talc use is associated with an increased risk of gynecologic malignancies, especially ovarian neoplasms, and talc particles have been found in the pathologic specimens of gynecologic malignancies. 25<28 Despite evidence against the use of talcum powder in the medical literature, talcum powder is widely available in the United States. We found that 22.8% of postmenopausal women reported talcum powder use within the last 3 months. This highlights the need for both provider awareness and woman education.
Another practice that has been shown to cause harm is douching. The practice of douching leads to a disturbance of the normal vaginal flora, which allows for an increase in bacteria vaginosis and other pathogenic organisms, including sexually transmitted infections. 10 Douching is highly discouraged in the medical literature; however, the practice of douching is still common. Twenty-five to 70% of reproductiveage women report douching. 29<34 Douching has been implicated as an independent risk factor for pelvic inflammatory disease, sexually transmitted diseases, cervical cancer, and ectopic pregnancy in reproductive-age women. 29<31 We found that 8% of postmenopausal women reported douching within the last 3 months.
Accurate diagnosis is essential for the appropriate treatment of vulvovaginal symptoms. Contact dermatitis is the most common cause of chronic vaginitis in women. 35 Other causes of vaginitis and vulvar pruritus include recurrent vulvovaginal candidiasis, atrophic vaginitis, vulvar vestibulitis, lichen simplex chronicus, and lichen sclerosus. 35 The multiple causes of chronic vaginitis and vulvar pruritus in women highlight the need for an accurate diagnosis; if contact dermatitis is the true underlying cause, self-treatment with OTC antifungal preparations may worsen symptoms. 7, 8 Our report on the treatments used by postmenopausal women was limited by the women we surveyed. This study recruited postmenopausal women actively seeking gynecologic care, limiting the generalizability of our findings. Women not seeking gynecologic care may have different OTC product use and perineal hygiene practices. We have only included 114 women, which may lead to some reported percentages being smaller or larger than actual OTC product use or perineal hygiene practices in the United States. However, owing to limited data on this topic, especially in postmenopausal women, we believe that our findings add valuable insight to the practices of postmenopausal women. In addition, our study included older women (mean age, 66 y), with a low number of minorities participating. We hypothesize that different cultures may have different hygiene practices. This is an area for future study. Because this research project was limited to baseline data collection and women were not followed prospectively over time, a causal relationship between OTC products and vulvovaginal skin symptoms cannot be established in this study. Despite these limitations, this project adds valuable insight to the self-management strategies of vulvovaginal symptoms in postmenopausal women.
CONCLUSIONS
Our study highlights the need for providers to ask postmenopausal women about OTC product use and perineal hygiene habits. Specifically, more than half of women use some form of OTC product. Douching and talcum powder use have been reported by 8% and 23% of postmenopausal women, respectively. Provider awareness is important to encourage inquiry about these practices, and targeted interventions are warranted to decrease known harmful practices in women.
